TransCode Therapeutics, Inc. (RNAZ) Earnings History
Annual and quarterly earnings data from 2018 to 2024
Loading earnings history...
RNAZ EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RNAZ Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export RNAZ earnings history in CSV or JSON format
Free sign-in required to download data
TransCode Therapeutics, Inc. (RNAZ) Earnings Overview
As of May 8, 2026, TransCode Therapeutics, Inc. (RNAZ) reported trailing twelve-month net income of -$27M, reflecting +98.6% year-over-year growth. The company earned $-32.55 per diluted share over the past four quarters.
Looking at the long-term picture, RNAZ's historical earnings data spans multiple years. The company achieved its highest annual net income of -$453,440 in fiscal 2018.
TransCode Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARWR (-$301M net income, -0.2% margin), NTLA (-$413M net income, -609.9% margin), SRPT ($65M net income, -32.5% margin), RNAZ has comparable earnings metrics. Compare RNAZ vs ARWR →
RNAZ Earnings vs Peers
Earnings metrics vs comparable public companies
RNAZ Historical Earnings Data (2018–2024)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$17M | +9.7% | -$16M | $-47.14 | - | - |
| 2023 | -$19M | -5.6% | -$19M | $-3453.53 | - | - |
| 2022 | -$18M | -156.7% | -$19M | $-1080.00 | - | - |
| 2021 | -$7M | -192.0% | -$6M | $-648.00 | - | - |
| 2020 | -$2M | -286.0% | $-726,604 | $-293.76 | - | - |
| 2019 | $-607,212 | -33.9% | $-456,865 | $-72.00 | - | - |
| 2018 | $-453,440 | - | $-383,996 | $-2359.09 | - | - |
See RNAZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNAZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RNAZ vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRNAZ — Frequently Asked Questions
Quick answers to the most common questions about buying RNAZ stock.
Is RNAZ growing earnings?
RNAZ EPS is $-32.55, with earnings growth accelerating to +98.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-27M.
What are RNAZ's profit margins?
TransCode Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are RNAZ's earnings?
RNAZ earnings data spans 2018-2024. The accelerating earnings trend is +98.6% YoY. Historical data enables comparison across business cycles.